3. Geographicexpansion Auryxia is already approved for sale in Japan, where it is currently being marketed under the brand name Riona by marketing partner Torii Pharmaceutical, which is a subsidiary of Japan Tobacco. Keryxreceives royalty payments based onnet sales of Riona and could also receive $55 million in additional milestones payments if sales go well. With an estimated 280,000 patients in Japan on dialysis, the market opportunity looks huge.